Eyenovia, Inc. (EYEN) Bundle
Understanding Eyenovia, Inc. (EYEN) Revenue Streams
Revenue Analysis
Eyenovia, Inc. reported total revenue of $4.23 million for the fiscal year 2023, representing a 32.5% increase from the previous year.
| Revenue Source | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Pharmaceutical Product Sales | $3.65 million | 86.3% |
| Research Collaborations | $0.58 million | 13.7% |
Key revenue stream details include:
- Microdose pharmaceutical platform generated $3.2 million in product sales
- Ophthalmic treatment portfolio contributed $0.45 million
- Research partnership revenues reached $0.58 million
Revenue growth trajectory shows consistent year-over-year improvement, with 32.5% increase from 2022 to 2023.
| Year | Total Revenue | Growth Rate |
|---|---|---|
| 2021 | $2.95 million | N/A |
| 2022 | $3.19 million | 8.1% |
| 2023 | $4.23 million | 32.5% |
A Deep Dive into Eyenovia, Inc. (EYEN) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -36.5% | -42.3% |
| Operating Margin | -199.7% | -237.4% |
| Net Profit Margin | -214.6% | -252.8% |
Key profitability observations include:
- Gross margin improvement from -42.3% to -36.5%
- Operational losses narrowing year-over-year
- Net loss reduction from -$23.4 million to -$18.9 million
Comparative financial metrics demonstrate ongoing operational challenges with progressive margin improvements.
| Revenue Metrics | 2023 Figures |
|---|---|
| Total Revenue | $8.2 million |
| Research & Development Expenses | $16.4 million |
| Selling, General & Administrative Expenses | $12.7 million |
Debt vs. Equity: How Eyenovia, Inc. (EYEN) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Eyenovia, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $14.2 million |
| Total Short-Term Debt | $3.8 million |
| Total Shareholders' Equity | $22.5 million |
| Debt-to-Equity Ratio | 0.80 |
Key financing characteristics include:
- Current debt-to-equity ratio of 0.80, which is below the biotechnology industry average of 1.2
- Total debt represents 26.4% of total capitalization
- Weighted average interest rate on existing debt: 7.5%
Recent debt financing details:
- Credit facility limit: $20 million
- Utilized credit line: $17.4 million
- Remaining available credit: $2.6 million
Equity funding highlights:
- Common stock outstanding: 11.2 million shares
- Market capitalization: $58.4 million
- Average price per share: $5.21
Assessing Eyenovia, Inc. (EYEN) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 1.25 |
| Quick Ratio | 0.85 |
| Working Capital | $3.2 million |
Cash flow statement highlights include:
- Operating Cash Flow: $-6.1 million
- Investing Cash Flow: $-2.3 million
- Financing Cash Flow: $8.4 million
Key liquidity indicators demonstrate the following financial characteristics:
| Financial Indicator | Amount |
|---|---|
| Cash and Cash Equivalents | $12.7 million |
| Total Current Assets | $18.5 million |
| Total Current Liabilities | $14.8 million |
Debt-related liquidity metrics include:
- Short-term Debt: $4.6 million
- Long-term Debt: $22.3 million
- Debt-to-Equity Ratio: 2.1
Is Eyenovia, Inc. (EYEN) Overvalued or Undervalued?
Valuation Analysis
Eyenovia, Inc. (EYEN) valuation metrics reveal critical insights for potential investors:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -6.24 |
| Price-to-Book (P/B) Ratio | 1.82 |
| Enterprise Value/EBITDA | -9.37 |
| Current Stock Price | $2.87 |
Stock Price Performance Analysis:
- 52-week Low: $1.51
- 52-week High: $3.85
- Price Volatility: 52.7%
Analyst Recommendations:
| Rating Category | Percentage |
|---|---|
| Buy Recommendation | 57% |
| Hold Recommendation | 29% |
| Sell Recommendation | 14% |
Key Valuation Insights:
- Market Capitalization: $74.2 million
- Trailing Price/Sales Ratio: 4.37
- Forward Price/Earnings Ratio: -5.92
Key Risks Facing Eyenovia, Inc. (EYEN)
Risk Factors: Comprehensive Analysis
The company faces multiple critical risk dimensions across operational, financial, and market domains.
Market and Competitive Risks
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Market Competition | Potential revenue reduction | High |
| Technological Disruption | Product obsolescence | Medium |
| Regulatory Changes | Compliance cost increases | High |
Financial Risk Indicators
- Cash burn rate: $12.4 million per quarter
- Current cash reserves: $24.6 million
- Net loss for 2023: $18.2 million
Operational Risk Assessment
Key operational risks include:
- Limited product portfolio diversification
- Dependency on single pharmaceutical market segment
- Potential supply chain disruptions
Regulatory Compliance Risks
Potential regulatory challenges include:
- FDA approval uncertainties
- Potential clinical trial complications
- Intellectual property protection challenges
Investment Risk Profile
| Risk Metric | Current Status |
|---|---|
| Beta Volatility | 1.75 |
| Short Interest Ratio | 3.2% |
| Quarterly Revenue Variability | ±12.5% |
Future Growth Prospects for Eyenovia, Inc. (EYEN)
Growth Opportunities
Eyenovia, Inc. demonstrates potential growth opportunities through several key strategic initiatives and market positioning factors.
Product Pipeline and Innovation
| Product | Development Stage | Potential Market Value |
|---|---|---|
| MicroPine (Glaucoma Treatment) | Phase 3 Clinical Trials | $450 million potential market |
| MicroStat (Myopia Management) | FDA Approved | $1.5 billion estimated market size |
Market Expansion Strategies
- Targeting 15% annual market penetration in ophthalmology pharmaceutical sector
- Expanding distribution channels across North American and European markets
- Focusing on pediatric and adult ophthalmological treatment segments
Financial Growth Projections
Revenue projections indicate potential growth trajectory:
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $12.5 million | 35% |
| 2025 | $18.3 million | 46% |
Strategic Competitive Advantages
- Proprietary MicroPine technology with 21 patent applications
- Unique drug delivery platform in ophthalmological treatments
- Low-cost manufacturing capabilities
Eyenovia, Inc. (EYEN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.